Biogen says hello to HI-Bio, inking $1.15B buyout to expand in immunology

fiercebiotech.com Biogen is placing a $1.15 billion bet on Chris Viehbacher’s diversification vision. The upfront payment has secured Biogen a deal to buy Human Immunology Biosciences…

US FDA approves two biosimilars for blockbuster eye drug Eylea

aol.com The U.S. Food and Drug Administration (FDA) on Monday approved two close copies of Regeneron Pharmaceuticals' Eylea, its first-ever clearance to biosimilar versions of the…

Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another

benzinga.com Thursday, Ionis Pharmaceuticals Inc IONS and Biogen Inc BIIB decided to terminate the development of BIIB105 (ION541), an investigational antisense oligonucleotide (ASO) for…

Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment

investors.com Biogen stock jumped early Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation. The post Biogen Stock Continues Its 20% Sprint On…

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early…

benzinga.com TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. BIIB Corporate headquarters:…

Lightning Round: We're only in the middle of Micron's roll higher, says Jim Cramer

youtube.com 'Mad Money' host Jim Cramer weighs in on stock including: Biogen, Kratos, Micron, Bank of America, Fidelis Insurance, Jfrog, and ...